The recent development of potent and selective small molecule inhibitors of EZH2 has revealed that EZH2 mutant-bearing DLBCL cells are highly sensitive to EZH2 inhibition [18], [19], [20], [21], [22]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.